Leczenie chorego z zespołem objawów, a nie diagnoz – możliwości citalopramu Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2022
Słowa kluczowe:
citalopram, depresja, objawy lękowe, zaburzenia lękowo-depresyjne, zaburzenia urojeniowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Citalopram to lek przeciwdepresyjny z grupy SSRI, który jest szeroko stosowany w depresji, zaburzeniach lękowych i problemach ze snem. Jego wysoka skuteczność w połączeniu z korzystnym profilem tolerancji sprawia, że może być stosowany u pacjentów starszych. W takich sytuacjach należy jednak pamiętać o dostosowaniu dawki do stanu pacjenta i unikaniu interakcji z innymi lekami często stosowanymi w tej grupie chorych. W pracy przedstawiono dwa opisy przypadków zastosowania citalopramu u chorych w trudnych sytuacjach diagnostycznych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Gładka, A., & Rymaszewska , J. (2022). Leczenie chorego z zespołem objawów, a nie diagnoz – możliwości citalopramu . Medycyna Faktów , 15(3(56), 347-352. https://doi.org/10.24292/01.MF.0322.13
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. WHO Figure: Crude suicide rate (access: 13.06.2021).
2. Beck AT, Rush AJ, Shaw BF et al. Cognitive Therapy of Depression. Guilford Press, New York 1979.
3. Stahl SM. Prescriber’s Guide Seventh Edition. Cambridge University Press. 2021.
4. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998; 51(3): 215-35.
5. Charakterystyka produktu leczniczego: citalopram.
6. Cipriani A, Purgato M, Furukawa TA et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012; 7(7): CD006534. http://doi.org/10.1002/14651858.CD006534.pub2.
7. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive d isorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128): 1357-66. http://doi.org/10.1016/ S0140-6736(17)32802-7.
8. Cipriani A, Purgato M, Furukawa TA et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012; 7(7): CD006534. http://doi.org/10.1002/14651858.CD006534.pub2.
9. Lavretsky H, Reinlieb M, Cyr N St et al. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015; 172(6): 561-9. http://doi.org/10.1176/appi.ajp.2014.14070889.
10. Zisook S, Trivedi MH, Warden D et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STAR*D study. J Affect Disord. 2009; 117: 63-73. http://doi.org/10.1016/j.jad.2009.01.002.
11. Porsteinsson AP, Drye LT, Pollock BG et al; CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014; 311(7): 682-91. http://doi.org/10.1001/jama.2014.93.
12. Zorick T, Okita K, Mandelkern MA et al. Effects of Citalopram on Cue-Induced Alcohol Craving and Thalamic D2/3 Dopamine Receptor Availability. Int J Neuropsy chopharmacol. 2019; 22(4): 286-91. http://doi.org/10.1093/ijnp/pyz010.
13. Paret C, Niedtfeld I, Lotter T et al. Single-Dose Effects of Citalopram on Neural Responses to Affective Stimuli in Borderline Personality Disorder: A Randomized Clinical Trial. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021; 6(8): 837-45. http://doi.org/10.1016/j.bpsc.2021.02.002.
14. Edes AE, McKie S, Szabo E et al. Increased activation of the pregenual anterior cingulate cortex to citalopram challenge in migraine: an fMRI study. BMC Neurol. 2019; 19(1): 237. http://doi.org/10.1186/s12883-019-1478-0.
15. Arnone D, Wise T, Walker C et al. The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 84(Pt A): 152-9.
16. Edinoff AN, Akuly HA, Hanna TA et al. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021; 13(3): 387-401. http://doi.org/10.3390/neurolint13030038.
17. Bazire S. Psychotropic Drug Directory 2018. The Professionals’ Pocket Handbook and Aide Memoire. Lloyd-Reinhold Publications Limited©Stephen Bazire 2020.
2. Beck AT, Rush AJ, Shaw BF et al. Cognitive Therapy of Depression. Guilford Press, New York 1979.
3. Stahl SM. Prescriber’s Guide Seventh Edition. Cambridge University Press. 2021.
4. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998; 51(3): 215-35.
5. Charakterystyka produktu leczniczego: citalopram.
6. Cipriani A, Purgato M, Furukawa TA et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012; 7(7): CD006534. http://doi.org/10.1002/14651858.CD006534.pub2.
7. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive d isorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128): 1357-66. http://doi.org/10.1016/ S0140-6736(17)32802-7.
8. Cipriani A, Purgato M, Furukawa TA et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012; 7(7): CD006534. http://doi.org/10.1002/14651858.CD006534.pub2.
9. Lavretsky H, Reinlieb M, Cyr N St et al. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015; 172(6): 561-9. http://doi.org/10.1176/appi.ajp.2014.14070889.
10. Zisook S, Trivedi MH, Warden D et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STAR*D study. J Affect Disord. 2009; 117: 63-73. http://doi.org/10.1016/j.jad.2009.01.002.
11. Porsteinsson AP, Drye LT, Pollock BG et al; CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014; 311(7): 682-91. http://doi.org/10.1001/jama.2014.93.
12. Zorick T, Okita K, Mandelkern MA et al. Effects of Citalopram on Cue-Induced Alcohol Craving and Thalamic D2/3 Dopamine Receptor Availability. Int J Neuropsy chopharmacol. 2019; 22(4): 286-91. http://doi.org/10.1093/ijnp/pyz010.
13. Paret C, Niedtfeld I, Lotter T et al. Single-Dose Effects of Citalopram on Neural Responses to Affective Stimuli in Borderline Personality Disorder: A Randomized Clinical Trial. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021; 6(8): 837-45. http://doi.org/10.1016/j.bpsc.2021.02.002.
14. Edes AE, McKie S, Szabo E et al. Increased activation of the pregenual anterior cingulate cortex to citalopram challenge in migraine: an fMRI study. BMC Neurol. 2019; 19(1): 237. http://doi.org/10.1186/s12883-019-1478-0.
15. Arnone D, Wise T, Walker C et al. The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 84(Pt A): 152-9.
16. Edinoff AN, Akuly HA, Hanna TA et al. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021; 13(3): 387-401. http://doi.org/10.3390/neurolint13030038.
17. Bazire S. Psychotropic Drug Directory 2018. The Professionals’ Pocket Handbook and Aide Memoire. Lloyd-Reinhold Publications Limited©Stephen Bazire 2020.